Cited by 22Thyroid Disorders and TreatmentsFibroblast Growth Factor ResearchBone Metabolism and Diseases

Regulation of Fibroblast Growth Factor Receptor-1 (Fgfr1) by Thyroid Hormone: Identification of a Thyroid Hormone Response Element in the Murine Fgfr1 Promoter

O’Shea, Patrick J., Guigon, Celine J., Williams, Graham R., Cheng, Sheue-yann·2007·Endocrinology

Abstract

T3 is essential for normal skeletal development, acting mainly via the TRα1 nuclear receptor. Nevertheless, the mechanisms of T3 action in bone are poorly defined. Fibroblast growth factor receptor-1 (FGFR1) is also essential for bone formation. Fgfr1 expression and activity are positively regulated by T3 in osteoblasts, and in mice that harbor a dominant negative PV mutation targeted to TRα1 or TRβ, Fgfr1 expression is sensitive to skeletal thyroid status. To investigate mechanisms underlying T3 regulation of FGFR1, we obtained primary calvarial osteoblasts from wild-type and TRβPV/PV littermate mice. T3 treatment increased Fgfr1 expression 2-fold in wild-type cells, but 8-fold in TRβPV/PV osteoblasts. The 4-fold increased T3 sensitivity of TRβPV/PV osteoblasts was associated with a markedly increased ratio of TRα1:TRβ1 expression that resulted from reduced TRβ1 expression in TRβPV/PV osteoblasts compared with wild-type. Bioinformatics and gel shift studies, and mutational analysis, identified a specific TR binding site 279–264 nucleotides upstream of the murine Fgfr1 promoter transcription start site. Transient transfection analysis of a series of Fgfr1 promoter 5′-deletion constructs, of a mutant reporter construct, and a series of heterologous promoter constructs, confirmed that this region of the promoter mediates a TR-dependent transcriptional response to T3. Thus, in addition to indirect regulation of FGFR1 expression by T3 reported previously, T3 also activates the Fgfr1 promoter directly via a thyroid hormone response element located at positions −279/−264.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/en.2007-0114

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 47 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
O’Shea, P. J., Guigon, C. J., Williams, G. R., & Cheng, S.-Y.
Affiliations
  • Gene Regulation Section (P.J.O, C.J.G., S.C.), Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4264;
  • Imperial College London (GB)
  • National Institutes of Health (US)
Corresponding author
Cheng, Sheue-yann
Venue
Endocrinology
Published
2007-12-01
Volume
148
Issue
12
Pages
5966-5976
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2054567390
Cited by
22
References
47
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2013: 3 · 2012: 2
FWCI
0.97
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • European Commission
  • National Institutes of Health
  • National Cancer Institute (20892)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
FGFR1, thyroid hormones, thyroid hormone response element, thyroid hormone receptor beta 1, thyroid hormone receptor alpha 1, osteoblasts, bone formation, transcriptional regulation, calvarial osteoblasts
MeSH terms
Animals, Base Sequence, Cells, Cultured, Enzyme-Linked Immunosorbent Assay, Gene Expression Regulation, Molecular Sequence Data, Osteoblasts, Promoter Regions, Genetic, Protein Binding, Thyroid Hormones, Reverse Transcriptase Polymerase Chain Reaction, Response Elements, Electrophoretic Mobility Shift Assay, Thyroid Hormone Receptors alpha, Thyroid Hormone Receptors beta, Mice, Receptor, Fibroblast Growth Factor, Type 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review